^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    docetaxel

    i
    Other names: NSC628503, NSC-628503, RP56976, RP-56976, XPR6976, NSC 628503, RP 56976, XPR 6976, XRP-6976
    Company:
    Generic mfg.
    Drug class:
    Microtubule inhibitor
    Related drugs:
    1d
    Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical Study (clinicaltrials.gov)
    P1, N=94, Not yet recruiting, Zhongda Hospital
    New P1 trial
    |
    docetaxel • Nubeqa (darolutamide) • goserelin acetate • Synribo (omacetaxine mepesuccinate)
    1d
    VA STARPORT: Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer (clinicaltrials.gov)
    P2/3, N=464, Recruiting, VA Office of Research and Development | Trial primary completion date: Mar 2026 --> Sep 2026
    Trial primary completion date
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • prednisone • bicalutamide • apalutamide • triptorelin • goserelin acetate • flutamide • nilutamide • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension
    1d
    HARMONY: Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations (clinicaltrials.gov)
    P2, N=0, Withdrawn, Qian Qin | Trial completion date: Apr 2028 --> Jan 2029 | Trial primary completion date: Apr 2027 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD54L (DNA Repair And Recombination Protein RAD54)
    |
    docetaxel • abiraterone acetate • Akeega (abiraterone/niraparib)
    1d
    A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment (clinicaltrials.gov)
    P3, N=438, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    New P3 trial
    |
    paclitaxel • docetaxel • irinotecan
    1d
    A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer (clinicaltrials.gov)
    P3, N=1800, Recruiting, Shanghai JMT-Bio Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide • epirubicin • anbenitamab (KN026)
    1d
    Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study (clinicaltrials.gov)
    P2, N=40, Recruiting, Mayo Clinic | Trial completion date: Mar 2028 --> Mar 2030 | Trial primary completion date: Mar 2026 --> Mar 2030
    Trial completion date • Trial primary completion date
    |
    cisplatin • docetaxel • albumin-bound paclitaxel
    2d
    A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer (clinicaltrials.gov)
    P3, N=596, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • trastuzumab brengitecan (BL-M07D1)
    2d
    InavoPC: A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=100, Recruiting, Hoffmann-La Roche | N=32 --> 100 | Trial primary completion date: May 2027 --> Mar 2028
    Enrollment change • Trial initiation date • Trial primary completion date
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • Itovebi (inavolisib)
    2d
    A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer (clinicaltrials.gov)
    P2, N=63, Recruiting, Asan Medical Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Jun 2025 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    docetaxel • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    3d
    Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=68, Completed, Asan Medical Center | Recruiting --> Completed
    Trial completion • pMMR
    |
    MSI (Microsatellite instability)
    |
    Imfinzi (durvalumab) • docetaxel • Imjudo (tremelimumab-actl) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    4d
    GEN1046 Safety Trial in Patients With Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=429, Active, not recruiting, Genmab | Trial completion date: Feb 2026 --> Aug 2026
    Trial completion date • First-in-human
    |
    Keytruda (pembrolizumab) • docetaxel • acasunlimab (GEN1046)
    4d
    HypProMet: Evaluation of Hypnosis in Virtual Reality on the Anxiety of Patients With Metastatic Prostate Cancer Over Chemotherapy (clinicaltrials.gov)
    P=N/A, N=53, Completed, Saint-Gregoire Private Hospital Center | Recruiting --> Completed | Trial completion date: Feb 2027 --> Feb 2026 | Trial primary completion date: Dec 2026 --> Dec 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    docetaxel